Literature DB >> 35419275

Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma.

Chaeyeong Kim1,2, Gyeyeong Kong1,2, Hyunji Lee1,2,3, Quangdon Tran1,2,4, Thuy-Trang T Vo1,2, So Hee Kwon5, Jisoo Park3, Seon-Hwan Kim6, Jongsun Park1,2.   

Abstract

Scavenger receptor class F member 2 (SCARF2) is expressed by endothelial cells with very large cytoplasmic domains and is the second isotype, also known as scavenger receptor expressed by endothelial cells 2 (SREC-2). SREC-1 plays an important role in the binding and endocytosis of various endogenous and exogenous ligands. Many studies have been carried out on modified low-density lipoprotein internalization activity, but there have been few studies on SCARF2. Higher expression of SCARF2 has been found in glioblastoma (GBM) than normal brain tissue. Through analysis of The Cancer Genome Atlas database, it was confirmed that SCARF2 is widely expressed in GBM, and increased SCARF2 expression correlated with a poor prognosis in patients with glioma. The results of this study showed that the expression of SCARF2 is increased in GBM cell lines and patients, suggesting that SCARF2 may be a potential diagnostic marker and therapeutic molecule for cancers including glioma.
© The Author(s) under exclusive licence to Korean Society of Toxicology 2022.

Entities:  

Keywords:  Biomarker; Cancer; Endocytosis; Glioblastoma; SCARF2

Year:  2022        PMID: 35419275      PMCID: PMC8960497          DOI: 10.1007/s43188-022-00125-5

Source DB:  PubMed          Journal:  Toxicol Res        ISSN: 1976-8257


  52 in total

1.  Unmasking of a Recessive SCARF2 Mutation by a 22q11.12 de novo Deletion in a Patient with Van den Ende-Gupta Syndrome.

Authors:  M F Bedeschi; L Colombo; F Mari; K Hofmann; A Rauch; B Gentilin; A Renieri; D Clerici
Journal:  Mol Syndromol       Date:  2011-05-18

2.  van den Ende-Gupta syndrome: evidence for genetic heterogeneity.

Authors:  Gabriela F Leal; Elias O Silva
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

3.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

4.  Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

Authors:  Georgia Paraskevakou; Cory Allen; Takafumi Nakamura; Paula Zollman; C David James; Kah Whye Peng; Mark Schroeder; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2007-02-13       Impact factor: 11.454

5.  Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells.

Authors:  Junhong Zhao; Qiaoyi Liang; Kin-Fai Cheung; Wei Kang; Raymond W M Lung; Joanna H M Tong; Ka Fai To; Joseph J Y Sung; Jun Yu
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

6.  Reoperations of patients with low-grade gliomas in eloquent or near eloquent brain areas.

Authors:  Wojciech Kaspera; Krzysztof Majchrzak; Barbara Bobek-Billewicz; Anna Hebda; Gabriela Stasik-Pres; Henryk Majchrzak; Piotr Ladziński; Agnieszka Machowska-Majchrzak
Journal:  Neurol Neurochir Pol       Date:  2013 Mar-Apr       Impact factor: 1.621

Review 7.  Photodynamic Therapy for the Treatment of Glioblastoma.

Authors:  Samuel W Cramer; Clark C Chen
Journal:  Front Surg       Date:  2020-01-21

Review 8.  Circulating biomarkers in patients with glioblastoma.

Authors:  Juliana Müller Bark; Arutha Kulasinghe; Benjamin Chua; Bryan W Day; Chamindie Punyadeera
Journal:  Br J Cancer       Date:  2019-10-31       Impact factor: 7.640

9.  Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.

Authors:  Raghupathy Vengoji; Pranita Atri; Muzafar A Macha; Parthasarathy Seshacharyulu; Naveenkumar Perumal; Kavita Mallya; Yutong Liu; Lynette M Smith; Satyanarayana Rachagani; Sidharth Mahapatra; Moorthy P Ponnusamy; Maneesh Jain; Surinder K Batra; Nicole Shonka
Journal:  J Exp Clin Cancer Res       Date:  2021-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.